Cargando…

Drug Repurposing of Metabolic Agents in Malignant Glioma

Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s met...

Descripción completa

Detalles Bibliográficos
Autores principales: Seliger, Corinna, Hau, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164672/
https://www.ncbi.nlm.nih.gov/pubmed/30223473
http://dx.doi.org/10.3390/ijms19092768
_version_ 1783359656539717632
author Seliger, Corinna
Hau, Peter
author_facet Seliger, Corinna
Hau, Peter
author_sort Seliger, Corinna
collection PubMed
description Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed.
format Online
Article
Text
id pubmed-6164672
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61646722018-10-10 Drug Repurposing of Metabolic Agents in Malignant Glioma Seliger, Corinna Hau, Peter Int J Mol Sci Review Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient’s metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed. MDPI 2018-09-14 /pmc/articles/PMC6164672/ /pubmed/30223473 http://dx.doi.org/10.3390/ijms19092768 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Seliger, Corinna
Hau, Peter
Drug Repurposing of Metabolic Agents in Malignant Glioma
title Drug Repurposing of Metabolic Agents in Malignant Glioma
title_full Drug Repurposing of Metabolic Agents in Malignant Glioma
title_fullStr Drug Repurposing of Metabolic Agents in Malignant Glioma
title_full_unstemmed Drug Repurposing of Metabolic Agents in Malignant Glioma
title_short Drug Repurposing of Metabolic Agents in Malignant Glioma
title_sort drug repurposing of metabolic agents in malignant glioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164672/
https://www.ncbi.nlm.nih.gov/pubmed/30223473
http://dx.doi.org/10.3390/ijms19092768
work_keys_str_mv AT seligercorinna drugrepurposingofmetabolicagentsinmalignantglioma
AT haupeter drugrepurposingofmetabolicagentsinmalignantglioma